Antibiotic Therapy in the Treatment of E. coli O157:H7
| Main Author: | |
|---|---|
| Language: | English |
| Published: |
University of Cincinnati / OhioLINK
2009
|
| Subjects: | |
| Online Access: | http://rave.ohiolink.edu/etdc/view?acc_num=ucin1230919332 |
| id |
ndltd-OhioLink-oai-etd.ohiolink.edu-ucin1230919332 |
|---|---|
| record_format |
oai_dc |
| spelling |
ndltd-OhioLink-oai-etd.ohiolink.edu-ucin12309193322021-08-03T06:13:08Z Antibiotic Therapy in the Treatment of E. coli O157:H7 McGannon, Colleen M. Microbiology O157:H7 Shiga toxin antibiotics hemolytic uremic syndrome bacteriophage <i>Escherichia coli</i> O157:H7 causes an estimated 73,000 of food borne illness annually. Varying levels of disease severity exist and include diarrhea, bloody diarrhea, and hemolytic uremic syndrome which can result in kidney damage or death. <i>E. coli</i> O157:H7 produces Shiga toxins 1 and/or 2, although it is Shiga toxin 2 that is linked to severe disease. Currently, a Shiga toxin-producing isolate will yield a positive diagnostic result, regardless of which Shiga toxin variant is produced. We have developed an ELISA that can differentiate between Shiga toxin 1 and Shiga toxin 2 in the presence of fecal material, and if used in the clinical setting, can increase the accuracy of prognosis for a patient infected with <i>E. coli</i> O157:H7. Epidemiological studies have suggested that antibiotics may be linked to HUS development. As such, we have completed an extensive study to determine which, if any, antibiotics are safe for the treatment of <i>E. coli</i> O157:H7. The data suggest that antibiotic-mediated Shiga toxin induction or reduction is based on the mechanism. Antibiotics that target DNA increase Shiga toxin production while protein synthesis inhibitors decrease Shiga toxin production. Human intestinal <i>E. coli</i> have been shown to amplify Shiga toxin. Our data suggest that protein synthesis inhibitors may be effective, even if the patient harbors a Shiga toxin-amplifying isolate, provided that the commensal isolate is susceptible to the antibiotic. Conversely, antibiotics would likely be of no benefit if the Shiga toxin-amplifier is resistant to the antibiotic. Future studies should focus on characterizing the flora of HUS patients, and examining antibiotic treatments within the context of these strains. 2009-04-17 English text University of Cincinnati / OhioLINK http://rave.ohiolink.edu/etdc/view?acc_num=ucin1230919332 http://rave.ohiolink.edu/etdc/view?acc_num=ucin1230919332 unrestricted This thesis or dissertation is protected by copyright: all rights reserved. It may not be copied or redistributed beyond the terms of applicable copyright laws. |
| collection |
NDLTD |
| language |
English |
| sources |
NDLTD |
| topic |
Microbiology O157:H7 Shiga toxin antibiotics hemolytic uremic syndrome bacteriophage |
| spellingShingle |
Microbiology O157:H7 Shiga toxin antibiotics hemolytic uremic syndrome bacteriophage McGannon, Colleen M. Antibiotic Therapy in the Treatment of E. coli O157:H7 |
| author |
McGannon, Colleen M. |
| author_facet |
McGannon, Colleen M. |
| author_sort |
McGannon, Colleen M. |
| title |
Antibiotic Therapy in the Treatment of E. coli O157:H7 |
| title_short |
Antibiotic Therapy in the Treatment of E. coli O157:H7 |
| title_full |
Antibiotic Therapy in the Treatment of E. coli O157:H7 |
| title_fullStr |
Antibiotic Therapy in the Treatment of E. coli O157:H7 |
| title_full_unstemmed |
Antibiotic Therapy in the Treatment of E. coli O157:H7 |
| title_sort |
antibiotic therapy in the treatment of e. coli o157:h7 |
| publisher |
University of Cincinnati / OhioLINK |
| publishDate |
2009 |
| url |
http://rave.ohiolink.edu/etdc/view?acc_num=ucin1230919332 |
| work_keys_str_mv |
AT mcgannoncolleenm antibiotictherapyinthetreatmentofecolio157h7 |
| _version_ |
1719432914685394944 |